Back to Search
ROY HERBST, M.D., PHD
M.D., PHD
Medical Oncology Physician
NPI: 1619060498IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
K4457(TX)
CMS Specialties
PrimaryMEDICAL ONCOLOGY
Education
JS WEILL MEDICAL COLLEGE, CORNELL UNIVERSITY
Class of 1991
Research & Publications (20)
Beyond doublet chemotherapy for advanced non-small-cell lung cancer: combination of targeted agents with first-line chemotherapy.
PMID 19289368·Clin Lung Cancer·2009
6-review
Comment on "Treatment of non-small cell lung cancer stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition)".
PMID 19059972·Chest·2008
8-other
Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC.
PMID 18997180·Oncologist·2008
6-review
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
PMID 17909199·J Clin Oncol·2007
3-trial
Enzastaurin, a protein kinase Cbeta- selective inhibitor, and its potential application as an anticancer agent in lung cancer.
PMID 17671157·Clin Cancer Res·2007
6-review
Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer.
PMID 17947484·Clin Cancer Res·2007
3-trial
Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis.
PMID 17243944·Expert Opin Investig Drugs·2007
6-review
Toxicities of antiangiogenic therapy in non-small-cell lung cancer.
PMID 17239287·Clin Lung Cancer·2006
6-review
Therapeutic options to target angiogenesis in human malignancies.
PMID 17064223·Expert Opin Emerg Drugs·2006
6-review
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
PMID 16043829·J Clin Oncol·2005
3-trial
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
PMID 16009949·J Clin Oncol·2005
3-trial
Angiogenesis and lung cancer: prognostic and therapeutic implications.
PMID 15886312·J Clin Oncol·2005
6-review
Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.
PMID 15753462·J Clin Oncol·2005
3-trial
Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer.
PMID 15638959·Clin Lung Cancer·2004
6-review
Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer.
PMID 15217967·Clin Cancer Res·2004
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1515 HOLCOMBE BLVD, 77030-4009
HOUSTON, TX 77030 - Phone
- (713) 792-6161
Quick Facts
- NPI
- 1619060498
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 35
- Publications
- 20
Are you this provider?
Claim Your Profile